Amy Kruse, PhD is General Partner and Chief Investment Officer at Satori Neuro, a venture fund dedicated to transformative solutions in mental health, neurotechnology, and human flourishing. A seasoned neuroscientist, investor, and technology leader, Amy previously served as General Partner at Prime Movers Lab, focusing on human augmentation and longevity. She serves on the boards of nine portfolio companies across both funds, including Gilgamesh Pharmaceuticals, Paradromics, Motif Neurotech, Attune Neurosciences, and Apollo Neuro, and is an independent director of Kitware.

Earlier, she was Chief Scientific Officer at Optios and Vice President and Chief Technology Officer at Cubic Global Defense, guiding advanced R&D programs. At DARPA, Amy pioneered performance-oriented neuroscience initiatives. A recognized thought leader, Amy serves on the External Oversight Committee of the NIH Blueprint MedTech program, is an expert reviewer for ARIA, the United Kingdom’s Advanced Research and Invention Agency, advises teams pursuing ARPA-H translational programs, advises BrainMind and Capital Factory, and mentors for the One Mind Accelerator and Health Wildcatters. She served on the Defense Science Board Summer Study on Autonomy and a National Academies committee on human–machine decision making, and writes the newsletter New in Human Flourishing.

Amy holds a PhD in Neuroscience and a BS in Cell and Structural Biology from the University of Illinois Urbana-Champaign, supported by a National Science Foundation Graduate Fellowship.